SciClone Pharmaceuticals (Holdings) Limited

SEHK:6600 Rapporto sulle azioni

Cap. di mercato: HK$11.4b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

SciClone Pharmaceuticals (Holdings) Performance dei guadagni passati

Il passato criteri di controllo 6/6

SciClone Pharmaceuticals (Holdings) has been growing earnings at an average annual rate of 11.2%, while the Pharmaceuticals industry saw earnings growing at 6% annually. Revenues have been growing at an average rate of 14.8% per year. SciClone Pharmaceuticals (Holdings)'s return on equity is 34.4%, and it has net margins of 35.6%.

Informazioni chiave

11.2%

Tasso di crescita degli utili

7.1%

Tasso di crescita dell'EPS

Pharmaceuticals Crescita del settore5.6%
Tasso di crescita dei ricavi14.8%
Rendimento del capitale proprio34.4%
Margine netto35.6%
Ultimo aggiornamento sui guadagni31 Dec 2023

Aggiornamenti sulle prestazioni recenti

Recent updates

SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 35% Price Boost Is Out Of Tune With Earnings

Apr 02
SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 35% Price Boost Is Out Of Tune With Earnings

Here's Why We Think SciClone Pharmaceuticals (Holdings) (HKG:6600) Might Deserve Your Attention Today

Dec 14
Here's Why We Think SciClone Pharmaceuticals (Holdings) (HKG:6600) Might Deserve Your Attention Today

Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Jun 19
Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Upcoming Dividend Will Be Larger Than Last Year's

May 31
SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Upcoming Dividend Will Be Larger Than Last Year's

Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Feb 17
Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Calculating The Intrinsic Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Dec 02
Calculating The Intrinsic Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

We Think You Should Be Aware Of Some Concerning Factors In SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Earnings

Oct 04
We Think You Should Be Aware Of Some Concerning Factors In SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Earnings

SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 25% Dip In Price Shows Sentiment Is Matching Earnings

Jul 27
SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 25% Dip In Price Shows Sentiment Is Matching Earnings

An Intrinsic Calculation For SciClone Pharmaceuticals (Holdings) Limited (HKG:6600) Suggests It's 45% Undervalued

Jun 02
An Intrinsic Calculation For SciClone Pharmaceuticals (Holdings) Limited (HKG:6600) Suggests It's 45% Undervalued

Ripartizione dei ricavi e delle spese

Come SciClone Pharmaceuticals (Holdings) guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.


Storia dei guadagni e delle entrate

SEHK:6600 Ricavi, spese e utili (CNY Millions )
DataRicaviGuadagniSpese G+ASpese di R&S
31 Dec 233,1561,122870171
30 Sep 233,0171,038839159
30 Jun 232,878953808147
31 Mar 232,814904781135
31 Dec 222,750855753124
30 Sep 222,706844738134
30 Jun 222,662833724145
31 Mar 222,590878726140
31 Dec 212,518923729134
30 Sep 212,259837742114
30 Jun 212,08977975385
31 Mar 212,00476670380
31 Dec 201,91975465375
30 Sep 202,00181761577
31 Dec 191,70861557988
31 Dec 181,40953553377
31 Dec 171,2132072883
30 Jun 171,16629458696
31 Mar 171,146258587111
31 Dec 161,112213591105
30 Sep 161,06024654488
30 Jun 161,07225755072
31 Mar 161,03418351582
31 Dec 151,02119150980
30 Sep 15991130488129
30 Jun 15913102458124
31 Mar 1587918644288
31 Dec 1483615642690
30 Sep 1477413342929
30 Jun 1479014046728
31 Mar 147706849957
31 Dec 137696651049
30 Sep 137807854135

Guadagni di qualità: 6600 has high quality earnings.

Margine di profitto in crescita: 6600's current net profit margins (35.6%) are higher than last year (31.1%).


Flusso di cassa libero e analisi degli utili


Analisi della crescita degli utili nel passato

Andamento degli utili: 6600's earnings have grown by 11.2% per year over the past 5 years.

Accelerare la crescita: 6600's earnings growth over the past year (31.2%) exceeds its 5-year average (11.2% per year).

Guadagni vs Settore: 6600 earnings growth over the past year (31.2%) exceeded the Pharmaceuticals industry -1%.


Rendimento del capitale proprio

ROE elevato: 6600's Return on Equity (34.4%) is considered high.


Rendimento delle attività


Rendimento del capitale investito


Scoprire le aziende con forti performance passate